The role of surgery for anaplastic thyroid carcinoma in the era of targeted therapeutics: A scoping review

Abstract

AbstractBackgroundQuestions exist regarding patient selection for surgery in anaplastic thyroid carcinoma (ATC), particularly with the advent of neoadjuvant‐targeted therapeutics. The present scoping review sought to evaluate what extent of surgical resection should be performed in ATC.MethodsA scoping review was carried out in accordance with Joanna Briggs Institute and the preferred reporting items for systematic reviews and meta‐analyses extension for scoping reviews (PRISMA‐ScR) protocols. Included studies were required to provide clear description of the surgery performed for ATC.ResultsThe final search identified 6901 articles. Ultimately only 15 articles including 1484 patients met inclusion criteria. A total of 765 patients (51.5%) underwent attempted curative intent surgery. The approach to resection of adjacent tissues varied between studies. Eight studies considered laryngeal ± pharyngeal resection (8/15, 53.3%), eight studies (53.3%) considered tracheal resection and again eight studies (53.3%) considered esophageal resection. More extensive resections increased morbidity without improving overall survival (OS) (<9 months in the 12 studies using a combination of surgery and chemoradiotherapy). In the three studies utilizing targeted therapy in addition to surgery, OS was notably improved while surgical resection following neoadjuvant therapy was less extensive.ConclusionsThere is no clear agreement in the literature regarding the limits of surgical resection in locoregionally advanced ATC. A definition of surgically resectable disease will be required to guide surgical decision making in ATC, particularly with the potential to reduce tumor burden using neoadjuvant targeted treatment in suitable patients.Level of evidenceIII